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Background: It is generally believed that malignant gliomas never metastasize outside the central nervous system
(CNS). However, the notion that oligodendrogliomas (OGDs) cells cannot spread outside CNS is being challenged.
Methods: We described in detail the clinical story of one patient with anaplastic OGD, which metastasized to
lymph nodes, bone marrowand bones Genetic analyses included detection of 1p and 19q chromosomal arms,
methylation status of MGMT promoter, and PTEN exon mutations. A search of worldwide literature was conducted
for reports of metastatic OGDs using NCBI-PubMed, with the keywords “extracranial”, “extraneural”, “oligodendroglioma”,
“oligodendrogliomas”, “metastatic”, “metastasis”, and “metastases”, in different combinations.
Results: An open biopsy of the infiltrated bones in our patient revealed that malignant cells had replaced the patient’s
marrow. Moreover, the diagnosis of multiple-organ metastases of anaplastic OGD was confirmed based on
immunohistochemical staining. Genetic analyses showed that the tumors originated from previously resected
brain lesions. None of the lesions had 1p and 19q deletions, but hypermethylation of MGMT promoter, and the
G→ A transversion at codon 234 of PTEN exon 2 were detected. Literatures review yielded 60 reports of metastatic
OGDs from 1951 to the present, which with our patient makes 61 cases. Concerning these 61 patients, there were 110
infiltrated sites correlated closely with primary OGDs. The most frequent metastatic sites were bone and bone marrow
(n = 47; 42.7%), lymph nodes (n = 22; 20.0%), liver (n = 7; 6.4%), scalp (n = 6; 5.5%), lung (n = 6; 5.5%), pleura (n = 4;
3.6%), chest wall (n = 3; 2.7%), iliopsoas muscle (n = 2; 1.8%), soft tissue (n = 2; 1.8%), and parotid gland (n = 2; 1.8%).
Conclusions: Extracranial metastases in anaplastic OGD are very rare but they do occur; bone and bone marrow may
be the most common sites. Detection of certain molecular markers such as deletion of 1p and 19q chromosomal arms,
hypermethylation of MGMT promoter, and characteristic PTEN exon mutations may help differentiate subtypes which
are more prone to extracranial metastases.
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It has been widely believed by neurosurgeons and neuroon-
cologists that malignant gliomas never metastasize outside
the central nervous system (CNS) [1]. However, this notion
has gradually proved incorrect. A review of 8000 tumors
involving the CNS found only 35 cases of extracranial
metastasis, including one oligodendroglioma (OGD) [2].
Liwnicz and Rubinstein [3] analyzed 116 cases in the
literature and found that the most common metastasizing
tumor type was glioblastoma multiforme (41.4%) followed
by medulloblastoma (26.7%), ependymoma (16.4%), and
astrocytoma (10.3%). and OGD (5.25%) was the least com-
mon tumor type to metastasize [3,4].
OGD is an uncommon diffuse glial tumor of central
neuroepithelial origin, accounting for ~4.2% of all primary
brain tumors. It has been mostly identified in adults,
with the highest incidence occurring in the fifth and
sixth decades of life, although it has also been reported in
children and adolescents [5]. Various forms of combination
therapy administered as comprehensive treatment have
improved the survival of patients with OGD or mixed
oligoastrocytoma [6].
Herein, we report a case of anaplastic oligodendroglioma
(AO) that metastasized to multiple lymph nodes, bone
marrow, and bones, including the bilateral iliac bones, the
right acetabulum, and multi-vertebral bodies.
Case presentation
A 45-year-old male who initially presented with a short
history of headache and vomiting was admitted to our
hospital in September 2011. No focal neurological deficit
was found on admission. Magnetic resonance imaging
(MRI) showed a left solid occipital tumor with mild con-
trast enhancing (Figure 1A,B,C). On 15 September 2011
he underwent a left solid occipital craniotomy with gross
total resection confirmed by subsequent MRI scans
(Figure 1D,E,F). The mass was yellow and friable. It was
neither hemorrhagic nor necrotic. The tumor margin was
ill defined. Photomicrographs of the resected tumor showed
that there were higher cell densities, densely packed round
cells with perinuclear haloes, microscopically round-to-
oblong cells with hyperchromatism and pleomorphism
(Figure 2A-D), clusters of capillary or plexiform capillaries
(Figure 2E,F), and obvious false fence structure-shaped ne-
crosis (Figure 2G,H). In addition, the irregular mitosis
densities were higher. A diagnosis was made of AO, WHO
(World Health Organization) grade III [7,8]. During the
subsequent 6 months, he was given 4 cycles of adjuvant
chemotherapy with temozolomide (TMZ; Schering, NJ),
a standard regimen [9] of 150–200 mg ·m-2 · d-1 for 5 days,
repeated every 28 days.
A repeated left occipital tumor resection was performed
8 months later (Figure 1G-L). Pathology also showed AO
WHO grade III, with similar histology. Subsequently,irradiation therapy concomitant with TMZ, 75 mg ·m-2 · d-1
for 42 days, was given and then 3 cycles of adjuvant
chemotherapy with a dose-intensive regimen of TMZ [10]
of 75 mg · m-2 · d-1 for 21 days, repeated every 28 days.
The patient experienced no significant hematological
toxicity, but he came to have difficulties in understanding
and remembering.
In October 2012, 5 months after the final occipital
resection, he presented with a 3-week history of lumbar
and right hipbone pain, and was hospitalized again in
November 2012. Regretfully, brain MRI showed evident
progression of the intracranial lesion (Figure 1M-O). There
was a solid enhancing lesion of high signal intensity on
T2-weighted MR images, and low-intensity signals in the
temporal area. The new lesion was thought to be a recur-
rent tumor with malignant transformation (Figure 1M-O).
MR images of the spine showed diffuse patchy areas of
increased signal intensity and abnormal enhancement
of the T7, T10, T12, L2, L3, L5, and S1 vertebral bodies
(Figure 1P,Q).
Subsequent bone scintigraphy and positron emission
tomography (PET)-computed tomography (CT) scans
revealed more multifocal invasion. A whole body 99mTc-
methylene diphosphonate bone scan showed hyper-activity
in the right iliac bone and the tenth and twelfth thoracic
vertebral bodies (Figure 3). PET-CT scans also showed
multifocal invasion of the bilateral iliac bones, the right
acetabulum, the right femoral neck and the C4, T7, T10,
T11, T12, L2, L3, and S1 vertebral bodies (Figure 4A,B),
the lymph nodes at the left side of the eleventh thoracic
vertebral body (Figure 4C) and the right supraclavicular
region (Figure 4D).
A bone marrow smear of the right iliac bone showed
no plasmacytoma cells (Figure 5). An open biopsy of the
infiltrated right iliac bone revealed the replacement of
the patient’s marrow by malignant cells, which exhibited
nuclear pleomorphism (Figure 2I,J). The confirmed diag-
nosis of AO metastasis to bone marrow was based on
immunohistochemical staining. We simultaneously reviewed
and performed the tumor cell identification in the bone
marrow spaces as well as in the previously primary AO in
the brain. They were all strongly positive for isocitrate
dehydrogenase-1 (IDH1; Figure 6A,B) and Ki-67, with
proliferation index >80% (Figure 6C). They were also all
positive for the glial fibrillary acidic protein (GFAP) marker
(Figure 6D), which is positive in glial, Schwannian, and
ependymal tumors (all neural tumors), and for the marker
oligodendrocyte transcription factor (Oligo-2; Figure 6E).
These findings supported the CNS origin of the metastatic
cells. Further findings were all negative for other pertinent
immunohistochemical stains: epithelial membrane anti-
gen (EMA), O6– methylguanine-DNA methyltransferase
(MGMT) and vimentin (Figure 6F,G,H, respectively).
Multiple outside pathologists confirmed this diagnosis.
Figure 1 (See legend on next page.)
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Figure 1 Representative axial MR images with gadolinium, taken on initial admission. (A) T1-weighted MR image (T1WI); (B) Contrast-enhanced
T1WI and (C) T2-weighted MR image (T2WI) showing a left occipital tumor with mild contrast enhancing; (D) at one month follow up, T1WI;
(E) contrast-enhanced T1WI and (F) T2WI showing no apparent enhanced lesion; (G) 8 months later after the first surgery, T1WI; (H) contrast-enhanced
T1WI and (I) T2WI showing marked enhanced mass on the cavity and recurrence; (J) 48 h after the second surgery, T1WI; (K) contrast-enhanced T1WI,
and (L) T2WI showing no apparent enhanced lesion; (M) 8 months later after combination radiotherapy and chemotherapy, T1WI; (N) contrast-enhanced
T1WI and (O) T2WI showing marked enhanced mass of the wall in the posterior portion of the removal cavity and left temporal areas, and recurrence
of the enhanced tumor. (P, Q) 8 months later after combination radiotherapy and chemotherapy, sagittal spinal contrast-enhanced T1WI after
gadolinium infusion showing high-intensity mass lesion in (P) T7, T10, and T12 vertebral bodies (arrowheads) and (Q) T12, L2, L3, L5, and S1
vertebral bodies (arrows).
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admitted to the family ward and supportive care was
administered until his death on 19 January 2013.Materials and methods
Tissue samples
We collected and analyzed both the bone marrow from
the above mentioned open biopsy and the brain tumor
tissues resected in the first and second craniotomy. The
Human Research Committee of the Fourth Military Medical
University approved the use of human tissues, in accordance
with the Approval of Research Involving Human Subjects.
The patient’s custodians provided informed written consent.
All specimens were handled and made anonymous in
accordance with ethical and legal standards.DNA extraction
The bone marrow from the biopsy was decalcified using
ultrasonic decalcification with ethylenediaminetetraacetic
acid (EDTA) as described previously [11] and paraffin
embedded. DNA was extracted from the tumor tissues
as previously described [12,13]. In brief, DNA was isolated
by sodium dodecyl sulfate/proteinase K treatment, phe-
nol–chloroform extraction, and ethanol precipitation and
then dissolved and stored in 1× Tris-EDTA (TE) buffer.
DNA concentration was measured at optical density 260
(OD260), and purity was verified by OD260/OD280 ≈ 1.8.Fluorescent in situ hybridization (FISH) assay
Sections from the brain tumors and metastatic lesions
were evaluated with routine hematoxylin-eosin (H & E)
staining. FISH assays were also performed for molecular
characterization. Both the brain tumors and the meta-
static lesions were analyzed to perform dual-color FISH
assay as previously published [14]. Briefly, paired probes
for 1p36/1q25-q31 and 19q13/19p12 (Abbott Molecular)
were prepared [14]. Green and red fluorescent signals
were enumerated under a Leica microscope with appro-
priate filters. For each hybridization, a minimum of
40 non-overlapping nuclei were assessed for numbers
of green and red signals, counted separately by two
individuals.MGMT promoter methylation status
DNA from the tumor tissues was analyzed by performing a
methylation-specific polymerase chain reaction (MS-PCR)
assay, as previously published [15], to detect the status of
theMGMT promoter.
PCR single-strand conformation polymorphism (PCR-SSCP)
and DNA sequencing for phosphatase and tensin
homologue (PTEN) deleted on chromosome ten exons
PCR–SSCP assay was applied to elucidate the mutations
in exons 1–9 of the PTEN gene (Table 1) [16-18]. PCR
amplification was carried out in a final volume of 25 μL
containing 50 ng DNA, 2.5 μL of 10× PCR buffer,
1.5 mmol/L MgCl2, 10 pmol/L of each primer, 2.5 mmol/L
of each dNTP, and 1 U Taq DNA polymerase. The amplifi-
cation conditions were: an initial incubation at 95°C for
8 min; 35 cycles at 95°C for 30 s, 51–57°C for 45 s for each
primer specific to the PTEN exons (Table 1), and 72°C for
30 s; with a final extension at 72°C for 7 min. PCR products
were resolved in 2% agarose gels stained with ethidium
bromide with a 100-bp DNA ladder as a standard refer-
ence, and electrophoresed for 30 min at 100 V.
SSCP analyses of all PTEN exons were conducted sys-
tematically on the PCR products. Equal volumes (7 μL)
of the PCR products and loading buffer (95% formamide,
20 mM EDTA, 0.05% bromphenol blue, and 0.05% xy-
lene cyanol) were mixed and centrifuged for 15 s, heat-
denatured at 95°C for 7 min, snap-chilled on ice for
10 min, and resolved through an 8% non-denaturing
polyacrylamide gel (acrylamide to bisacrylamide, 29:1)
containing 50 mM Tris-borate (pH 7.5) and 2.5 mM
EDTA, and electrophoresed with 1× tris-borate-EDTA
buffer for 16 h at 14°C at a voltage of 100 V. Silver staining
was performed as previously described [19].
According to the PCR-SSCP results of genomic DNA,
the present sample was considered PCR-SSCP positive
based on the evident difference in the single strand strip
number and electrophoresis transference location [20].
Genomic DNA from the positive PCR-SSCP sample was
amplified again in a 40-μL reaction system for bidirec-
tional DNA sequencing. The amplified PCR products
were sequenced with an ABI PRISM 310 dye terminator
cycle sequencing ready reaction kit. The results were
compared using the GenBank database.
Figure 2 Representative photomicrographs of the tumor specimens. Higher cell densities (A, B; 100×, 200×, respectively, H & E) with
perinuclear haloes (C; 200×, H & E; arrows), and microscopically round-to-oblong cells with hyperchromatism and pleomorphism (D; 400×, H & E),
are compatible with AO. (E, F) Clusters of capillary or plexiform capillaries (arrows), and the irregular mitosis densities were higher (100×, 200×,
respectively, H & E). (G, H) Obvious false fence structure (thick arrows)-shaped necrosis (slim arrows; 100×, 200×, respectively, H & E). (I, J) After
the right iliac bone marrow needle biopsy, cells in the bone marrow specimen from the patient were small and round with a thin rim of eosinophilic
cytoplasm (400×, H & E).
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FISH analysis
None of the tumors from the resected brain lesions or the
metastatic lesions had the 1p (Figure 7A) or 19q deletions(Figure 7B). We were satisfied that, although the bone
marrow from the biopsy was decalcified via ultrasonic
decalcification and EDTA, the metastatic lesions remained
informative.
Figure 3 Representative emission computed tomography scans. (A) anterior scans, and (B) posterior scans, showed a hypermetabolically
abnormal uptake at the right iliac bone (arrowheads) and T10, and T12 vertebral bodies (arrows).
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The MSP-PCR assays of the tumors from the primary
brain lesions and autopsied metastasized tissues all
showed the methylated MGMT promoter (Figure 8), and
the result from the corresponding samples was nearly
identical.Figure 4 Representative whole body PET-CT scans. (A) and (B) Multiple
bilateral iliac bones, C4, T7, T11, T10, T12, L2, L3, S1 vertebral bodies and th
lymph node near the left side of the T11 vertebral body (arrows); (D) Focu
supraclavicular region (arrows).PTEN mutation
The case was considered PCR-SSCP-positive, and genomic
DNA from the samples was amplified for bidirectional
DNA sequencing. Compared with the sequences in the
GenBank database, the sequencing data of the patient
showed a transversion, “A” in place of “G” at codon 234foci of increased 18 F-fluoro-2-deoxyglucose (FDG) uptake at the
e right acetabulum; (C) Focus of increased 18 F-FDG uptake at the
s of increased 18 F-FDG uptake at the lymph node of the right
Figure 5 Representative scans of bone marrow smear. (A, B) No plasmocytoma cells were found (100× and 1000×, respectively).
Figure 6 Representative immunochemical markers in tumor specimens. (A, B) Positive reaction for IDH1 (100×, 200×, respectively). (C)
Positive reaction for Ki-67, with proliferating index >80% (200×). (D, E) Tumor cells were positive for GFAP and Oligo-2, respectively (200×).
(F, G, H) showed the tumor cells were negative for EMA, MGMT, and vimentin, respectively (200×).
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Table 1 PTEN primers used for single-strand conformation
polymorphism (SSCP) analysis




1 F1. 5’-TCCTCCTTTTTCTTCAGCCAC-3’ 56 147
R1. 5’-GAAAGGTAAAGAGGAGCAGCC-3’
2 F2. 5’-TGCATATTTCAGATATTTCTTTCCTT-3’ 57 155
R2. 5’-TTTGAAATAGAAAATCAAAGCATTC-3’
3 F3. 5’-TGTTAATGGTGGCTTTTTG-3’ 56 114
R3. 5’-GCAAGCATACAAATAAGAAAAC-3’
4 F4. 5’-TTCCTAAGTGCAAAAGATAAC-3’ 56 147
R4. 5’-TACAGTCTATCGGGTTTAAGT-3’
5 F5. 5’-TTTTTTTTTCTTATTCTGAGGTTATC-3’ 51 312
R5. 5’-GAAGAGGAAAGGAAAAACATC-3’
6 F6. 5’-AGTGAAATAACTATAATGGAACA-3’ 54 231
R6. 5’-GAAGGATGAGAATTTCAAGC-3’
7 F7. 5’-ATCGTTTTTGACAGTTTG-3’ 55 262
R7. 5’-TCCCAATGAAAGTAAAGTAGA-3’
8 F8. 5’-AGGTGACAGATTTTCTTTTTTA-3’ 52 394
R8. 5’-TAGCTGTACTCCTAGAATTA-3’
9 F9. 5’-CTTTCTCTAGGTFAAGCTGTACTT-3’ 55 231
R9. 5’-TTCATGGTGTTTTATCCCTCTTGA-3’
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polymorphism (Figure 9). No mutation was detected in
the other PTEN exons.
Discussion
Extraneural metastases from primary brain tumors are
rare [21] for reasons that remain obscure. Proposed initial
theories generally lack credibility among neurosurgeons
and neurooncologists; these include collapse of thin-walled
cerebral veins, the inability of neural tissue to grow outside
the CNS, and the lack of lymphatics in the brain [22]. MoreFigure 7 Representative FISH images from the right iliac bone. Some
2 red (1p36, arrows) and 2 green (1q25-q31, arrowheads) signals in scattere
(19p12, arrowheads) signals in scattered nuclei.accepted is the theory that because brain tumors present
earlier, there is less time for metastases to develop [21].
Another theory suggests that the intracerebral environment
is not sufficiently hostile to select out metastatic clones.
There is relatively little connective tissue stroma in the
brain compared with the rest of the body. It has also been
proposed that clones are not selected for the ability to
invade fibrous connective tissue and are thus not suited to
invade extracranial tissues [23]. The role of the blood–
brain barrier is also uncertain, albeit it does seem to have
a limited role in metastasis.
Despite the above theories, glioma does metastasize
outside the CNS, and most cases of extraneural metastasis
(nearly 96%) have occurred after surgical excision of
the primary tumor [24]. The most common glioma to
metastasize is glioblastoma multiforme, followed by
medulloblastoma and ependymoma [4], while OGD me-
tastasizes very rarely.
OGD is such a diffuse glial tumor. Extracranial metastasis
of the primary intracranial neoplasm is infrequent generally,
and it seemed to usually happen only in the setting of prior
neurosurgical resection [25]. OGDs are characterized by
multiple recurrences [25], extraneural spread is unusual,
and distant skeletal metastases are particularly infrequent.
We therefore undertook a worldwide literature review to
investigate further the incidence of extraneural metastases.
This yielded 60 previously reported metastatic OGDs from
1951 to the present, and our patient makes 61 (Table 2).
The review was performed using NCBI-PubMed with the
keywords “extracranial”, “extraneural”, “oligodendroglioma”,
“oligodendrogliomas”, “metastatic”, “metastasis”, and “me-
tastases” in different combinations. We also reviewed the
bibliography of the subsequently selected articles.
Of the 61 reported metastatic OGDs, 33 (54.1%) were
male, 17 (27.9%) were female, and in the remaining cases
18.0% gender was not reported (Table 3). Ten (16.4%)
patients were Asian, 30 (49.2%) were European, 18 (29.5%)signals are missing due to nuclear truncation. (A) No 1p deletion, with
d nuclei. (B) No 19q deletion with 2 red (19q13, arrows) and 2 green
Figure 8 Representative MSP-PCR for methylated MGMT promoter. NTC, non DNA template control; +, methylated; –, unmethylated; M,
DNA marker; the upper, middle, and lower bands are 140, 120, 100, and 80 bp, respectively.
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(4.9%) the ethnicities were unreported. There were 110
infiltrated sites correlated closely with primary OGDs. The
most frequent metastatic site was bone and bone marrow
(n = 47; 42.7%) followed by lymph nodes (n = 22; 20.0%),
liver (n = 7; 6.4%), scalp (n = 6; 5.5%), lung (n = 6; 5.5%),
pleura (n = 4; 3.6%), chest wall (n = 3; 2.7%), iliopsoas
muscle (n = 2; 1.8%), soft tissue (n = 2; 1.8%), parotid
gland (n = 2; 1.8%), and adrenal gland, spleen, thoracic
wall, pancreas, dorsal root ganglia, abdomen, spinal dura
mater, breast, and thymus gland with one lesion each
(n = 1; 0.9%).
The review indicated that bone and bone marrow are
the most common sites metastasizing from OGDs. In our
present case, systematic examination found multiple extra-
cranial metastases, including the vertebrae, lymph nodes,
bilateral iliac bones, and right acetabulum. Metastases in
these sites suggest that tumor cells were delivered via the
blood vessels and lymphatic system.Figure 9 Representative sequencing data showing the G→ A transve
primer; red, exon 2; purple, the transversion of A, showing the polymorphisPrimary neoplasm in the brain is generally considered
to spread in any of three ways: seeding through the
cerebral fluid pathway, local invasion, or spreading re-
motely through lymphatic and blood vessels [68]. It is
widely accepted that the brain and spinal cord contain no
lymphatic pathway. However, as the tumor cells infiltrate
the dura mater, extracranial metastasis by way of the
lymphatic system becomes possible, and could especially
happen after craniotomy. Surgical procedures can elevate
the risk of metastasis outside the nervous system by way
of the lymphatic system as well as the blood vessel.
Extraneural metastasis is considered correlated with
multiple craniotomies, shunt surgery, and long-term sur-
vival [39,69,70]. Extracranial metastasis without previous
surgical intervention is infrequent; among 282 reported
cases of glioma with metastases outside the CNS only 24
(8.5%) were spontaneous [71]. Most cases of extracranial
metastasis occur after craniotomy. Shunt surgery is re-
sponsible for seeding tumor cells by way of cerebrospinalrsion at codon 234 (arrows) of exon 2 in PTEN of the patient. Blue,
m.
Table 2 Review from the literature of 61 reported patients with oligodendroglioma with metastases outside the CNS
Patient no. Gender Subjects WHO grade Age at
diagnosis (y)







1 F British ODG, low grade early,
later *AO
25 Cervical lymph nodes, scalp,
lung, bone
84 * * James et al. 1951 [26]
2 F American ODG, *grade 7 Scalp, bone, soft tissue, liver 36 * * Spataro et al. 1968 [27]
3 F Austrian ODG, *grade 58 Bone 30 * * Jellinger et al. 1969 [28],
(also reported as
Schuster et al. 1976 [29])
4 M American *ODG, *grade 45 Bone marrow 17 * * Smith et al. 1969 [2]
5 * * ODG, initially low grade 3.5 Lymph nodes, lungs, adrenal 21 * * Kernohan 1971 [30]
6 F Scottish Malignant glioma, some
ODG features
21 Bone 9 * * Eade et al. 1971 [31]
7 M Scottish Small cell GBM with
regions of ODG
23 Bone 12 * *
8 M French *ODG, *grade 57 Lymph nodes, bone 20 * * Cappellaere et al.
1972 [32]
9 M French *ODG, *grade 22 Lymph nodes, bone, parotid
gland
25 * *
10 F British Malignant glioma, some
ODG features
30 Pleura 156 * * Brander et al. 1975 [33]
11 M German *ODG, *grade 40 Bone, lymph nodes, lungs 86 * * Kummer et al. 1977 [34]
12 * Canadian *ODG, *grade * Scalp * * * Chin et al. 1980 [35]
13 F American ODG, grade II 33 Bone, lymph nodes, scalp,
soft tissue
50 * * Ordonez et al. 1981 [36]
14 M Japanese Grade III 32 Bone 76 14 * Nakamura et al. 1985 [37]
15 M * ODG, malignant 41 Bone marrow 48 * * Newman et al. 1985 [38]
16 * Canadian ODG, *grade,
some astro
12 Bone, lymph nodes, scalp 104 * * Macdonald et al. 1989 [39]
17 * Canadian ODG, *grade 44 Cervical lymph nodes, bone, 48 * *
18 F Canadian ODG, grade III 36 Bone, lymph nodes 60 * *
19 * Canadian ODG, *grade,
some astro
32 Bone, lymph nodes, scalp 38 * *
20 * Canadian ODG, *grade 34 Bone 76+ * *
21 M Canadian ODG, grade III 27 Bone 37 * *
22 * Canadian ODG, *grade,
some astro
47 Bone 26+ * *














Table 2 Review from the literature of 61 reported patients with oligodendroglioma with metastases outside the CNS (Continued)
24 * German * * Cervical lymph nodes * * * Steininger et al. 1993 [41]
25 M British ODG, grade III 54 Bone marrow 12 * * Gerrard et al. 1995 [42]
26 * German Grade III * Cervical lymph nodes * 48 * Schroder et al. 1995 [43]
27 M Italian ODG, grade II 58 Chest wall, bone marrow,
possibly liver
48 * * Monzani et al. 1996 [44]
28 M British ODG, grade III 43 Bone marrow, liver 3 * * Dawson 1997 [45]
29 M Austrian ODG-astrocytoma
grade III
62 Thoracic wall, pleura, bone
marrow
288 6 * Finsterer et al. 1998 [46]
30 M Indian Grade III 50 Bone and bone marrow 7+ * * Anand et al. 2001 [47]
31 * Italian ODG, grade II 25 Bone 84+ * * Giordana et al. 2002 [48]
32 M Indian Grade III 50 Bone marrow 17 * * Sharma et al. 2003 [49]
33 M American Grade III 33 Bone marrow 38+ * * Choon et al. 2004 [50]
34 M Canadian Grade III 35 Bone 84 23 Allelic LOH of chromosome 1p
(1p-), a rise in serum alkaline
phosphatase
Morrison et al. 2004 [51]
35 F American ODG, grade II early,
later AO, grade III
41 Parotid gland 79+ 68 Codeletion of 1p/19q Wang et al. 2004 [52]
36 M American ODG, low grade early,
later AO, grade III
28 Bone marrow 120 5 Positive for S-100 marker with
immunohistochemical stain
Al-Ali et al. 2005 [23]
37 M American Atypical meningioma,
early, later AO, grade III
32 Bone, bone marrow, cervical
and thoracic lesions
168 27 Elevated serum lactate
dehydrogenase and alkaline
phosphatase, positive for
S-100, and GFAP with
immunohistochemical stain
Merrell et al. 2006 [53]
38 F American AO, grade III 71 Bone, bone marrow, 17 13 Codeletion of 1p/19q, positive
for S-100, and GFAP with
immunohistochemical stain,
elevated serum hemoglobin level
39 F Chinese ODG, *grade 64 Pleura, bone * 84 Positive for S-100, Olig2 and
GFAP with immunohistochemical
stain
Lee et al. 2006 [54]
40 M American ODG, grade II early,
later AO, grade III
15 Pleura, bone, lungs, adrenal
gland, chest, liver, abdomen
62 31 Codeletion of 1p/19q Bruggers et al. 2007 [55]
41 F Japanese AO, grade III 17 Spleen, liver, pancreas, bone,
spinal dura mater, dorsal
root ganglia, lungs, lymph
nodes, iliopsoas muscle
144 3 Markedly positive for Ki-67,
and positive for Olig2 with
immunohistochemical stain,
Uzuka et al. 2007 [56]
42 F Korean AO, grade III 48 Liver, lungs 28 27 Not presented Han et al. 2008 [4]














Table 2 Review from the literature of 61 reported patients with oligodendroglioma with metastases outside the CNS (Continued)
44 F Slovenian AO, grade III 54 Cervical and neck lymph
nodes
48 12 Positive for S-100, and GFAP
with immunohistochemical stain
Volavsek et al. 2009 [58]
45 F Slovenian AOA, grade III 30 Bone 58+ 17 Positive for GFAP with
immunohistochemical stain
46 M Japanese AO, grade III 53 Lymph nodes, bone, spinal
dura mater, thymus gland,
chest wall
30 24 Codeletion of 1p/19q Noshita N, et al. 2010 [59]
47 F Japanese AO, grade III 73 Cervical lesion 18+ 18 * Oshiro S, et al. 2010 [60]
48 M Dutch AO, grade III 59 Bone marrow 33 31 Codeletion of 1p/19q, positive
for S-100, and p53 with
immunohistochemical stain
Krijnen JL, et al. 2010 [61]
49 M Dutch *ODG, *grade 24 Bone marrow * 84 Not presented
50 M Dutch AO, grade III 34 Cervical lymph nodes, iliopsoas
muscle
* not presented Not presented
51 M Dutch AO, grade III 64 Axillary lymph nodes * 34 Not presented
52 M Dutch AO, grade III 72 Bone marrow * 6 Not presented
53 F Dutch *ODG, *grade 67 Bone marrow * 29 Not presented
54 M Dutch AO, grade III 62 Retroperitoneal lymph nodes * 21 Not presented
55 M Turkish AO, grade III 55 Bone marrow 23+ 11 Positive for GFAP with
immunohistochemical stain
Kural C, et al. 2011 [62]
56 M Chinese AO, grade III 37 Bone 58+ 37 Positive for S-100, and GFAP
with immunohistochemical
stain
Wu Y, et al. 2011 [63]
57 M Italian AO, grade III 40 Bone marrow 61 57 Positive for enolase, and GFAP
with immunohistochemical
stain
Cordiano V, et al.
2012 [64]
58 F Turkish ODG, *grade * Cervical lymphatic chain * 60 Codeletion of 1p/19q Can B, et al. 2012 [65]
59 M Turkish AO, grade III 58 Breast * * * Alacacioglu A, et al.
2012 [66]
60 M Irish AO, grade III 58 Bone 120+ 108 Codeletion of 1p/19q,
positive for GFAP with
immunohistochemical stain
Greene J, et al. 2013 [67]
61 M Chinese AO, grade III 45 Bone, bone marrow, lymph
nodes
16 13 No deletion of 1p/ 19q, PTEN
mutation in exon 2, MGMT
promoter methylated, positive
for IDH1, Ki-67, Olig2, and GFAP,




F: female, M: male, OS: overall survival, WHO: World Health Organization, LOH: loss of heterozygosity, ODG: oligodendroglioma, AO: anaplastic oligodendroglioma, AOA: anaplastic oligoastrocytoma, GBM: glioblastoma multiforme.
*Not provided in the corresponding literature.



















Male 33 54.1% (33/61)
Female 17 27.9% (16/61)
Not given 11 18.0% (11/61)
Subjects
Total 61
Asian 10 16.4% (10/61)
European 30 49.2% (30/61)
American & Canadian 18 29.5% (18/61)
Not given 3 4.9% (3/61)
Location of metastasis
Total Sites 110
Bone/bone marrow 47 42.7% (47/110)
Lymph node 22 20.0% (22/110)
Liver 7 6.4% (7/110)
Scalp 6 5.5% (6/ 110)
Lung 6 5.5% (6/ 110)
Pleura 4 3.6% (4/110)
Chest wall 3 2.7% (3/110)
Iliopsoas muscle 2 1.8% (2/110)
Soft tissue 2 1.8% (2/110)
Parotid gland 2 1.8% (2/110)
Other 9
Adrenal 1 0.9% (1/110)
Spleen 1 0.9% (1/109)
Thoracic wall 1 0.9% (1/110)
Pancreas 1 0.9% (1/110)
Dorsal root ganglia 1 0.9% (1/110)
Abdomen 1 0.9% (1/110)
Spinal dura mater 1 0.9% (1/110)
Breast 1 0.9% (1/110)
Thymus gland 1 0.9% (1/109)
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also raise the risk of extracranial metastases. Thus, in our
present case, craniotomy could be considered an influen-
cing factor in extracranial metastasis.
The median age of the 60 patients found through the
literature review was 40.0 years (range 3.5-73.0 y; Table 2).
The overall survival ranged from 3–288 months, with a
median of 38 months. These data are consistent with the
recent reports of AOs [57,63]. The survival time of our
patient was relatively shorter than the median, although
he was given the standard regimen recommended by theNational Comprehensive Cancer Net (NCCN) guidelines
[73]. His shorter survival and poor prognosis may be due,
firstly, to the presence of 1p/19q, which may have adversely
influenced the success of the recommended comprehensive
therapy, as combined deletion of the 1p and 19q chromo-
somal arms is expected in OGD [74]. Molecular studies
have revealed that deletions of chromosome 1p and 19q are
usually associated with longer survival in OGD, as well as a
better response to irradiation and chemotherapy. Tumors
with such a co-deletion are sensitive to comprehensive
therapy, with 90-100% of patients responding [74,75].
The overall survival for AOs is about 2–3 years for
those without the 1p/19q codeletion, compared with
6–7 years in those with 1p/19q loss [76,77]. For our patient,
the previously resected tumors from the brain lesions, as
well as the metastatic lesions, all had complete 1p and 19q
chromosomes. Thus the lack of deletion of 1p/19q may
have led to a shorter survival time under comprehensive
therapy.
A second contributing factor toward the poor prognosis
of the present case is the presence of the PTEN mutation,
which was shown in both brain lesions and extracranial
metastases. This may have made the patient more prone
to extracranial metastases. PTEN tumor suppressors are
located on human chromosome 10q23.3, which contains
nine exons and encodes a 47-kD dual-specific protein
phospholipid phosphatase with 403 amino acids [17].
PTEN mutations accompany nearly 50% of the cases with
a 10q deletion, suggesting that there might be another
progression-related target gene in this region [78]. PTEN
mutations and 10q deletions are more common in AOs
without 1p and 19q losses [79]. Infrequently AOs carry
activating mutations in the PIK3CA gene [80]. PTEN
mutations have also been studied for their involvement
in the pathogenesis of a number of human malignancies,
including glioma [80].
Different mutations in the PTEN locus, including frame-
shifts and missense mutations, have proved to be correlated
with human cancers [81,82]. These could result in early
termination of translation and immature gene products,
and subsequently lead to complete loss of vigor. In most
cases, mutations in PTEN were found to decrease phos-
phatase activity [19,83]. In the present study, our patient
definitely had a substitution mutation in PTEN at exon
2, which may have made him more prone to extracranial
metastases.
It must also be noted that, although our patient
underwent a chemotherapy regimen with TMZ, his condi-
tion nevertheless deteriorated more rapidly afterward. As
known, AOs are chemosensitive neoplasms that respond
to combined treatment with lomustine, vincristine and
procarbazine (i.e., PCV therapy), with 60-70% of patients
responding [84]. Studies have also shown that TMZ, the
oral alkylating agent that inhibits DNA replication by
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well tolerated in AO patients [85,86]. TMZ methylates
guanines in DNA at the O6 position, leading to base-pair
mismatch. The known O6– methylguanine (O6–MeG)
lesion causes DNA double-strand breaks and subsequent
cell death through autophagy, apoptosis, or both [87].
MGMT is the DNA repair enzyme that repairs the O6-
MeG lesion and is induced either by chemotherapeutic
agents or environmental carcinogens. Methylation of the
MGMT promoter or high levels of MGMT are thought to
be associated with resistance to TMZ [88]. Levin et al. [86]
reported that TMZ was active in patients with progressive
OGDs, and that a 1p deletion and low MGMT protein
expression could contribute to a better response to TMZ
treatment. For our patient, results of the MSP-PCR assays
of the primary brain lesions and autopsied metastatic
tissues all showed the methylated MGMT promoter.
However, we regret that although several cycles of
chemotherapy of TMZ were given, the patient still deteri-
orated rapidly and eventually succumbed. The reasons for
his failure to respond favorably to TMZ chemotherapy
remain to be explored.
Conclusions
In summary, extracranial metastases in AO do occur,
although they are very rare. Detection of molecular markers
such as combined deletion of the 1p and 19q chromosomal
arms, hypermethylation of the MGMT promoter, and
PTEN exon mutations may help elucidate which subtypes
of AO are more prone to extracranial metastases, which
would benefit these patients.
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